United States of America (USA) Drug Pricing and Reimbursement Landscape - Thematic Research

Table 1: International Drug Price Ratios for the Top 15 Medicare Part B Drugs, by 2018 Spend
Table 2: Average Impact of MFN Model on Reimbursements Rates for Oncology Practices
Table 3: Top 10 Oncology Drugs Impacted by the MFN Model
Table 4: Examples of 2021 Premium Rate Changes for Leading Health Insurers
Table 5: New Services Added to the Medicare Telehealth List

Figure 1: The US Spends Twice As Much on Healthcare As Comparable Countries
Figure 2: Timeline of the Trump Administration’s Drug Pricing Proposals 2018–2020
Figure 3: Beneficiaries Could Save Over 65% On Annual Out-of-Pockets Costs for Insulin
Figure 4: Top US Influencer Trends and Post Related to Drug Pricing in 2020
Figure 5: Number of Uninsured and Uninsured Rate Among the Nonelderly Population in the US (2008–2020)
Figure 6: Use of Telehealth Was Increasing Before the Pandemic, but Use Was Low Overall
Figure 7: Timeline of Key Regulatory and Policy Changes Related to Telemedicine in the US
Figure 8: Most Important Healthcare Issues for the US Election and Views on Party Nominee Approach
Figure 9: US Presidential Election Campaign Messages for the ACA
Figure 10: US Presidential Election Campaign Messages for Drug Pricing
Figure 11: Drug Pricing and Reimbursement Constraints Expected to Have the Greatest Impact in 2021